For those dummies like me - the Interleukin (IL-2) which was...

For those dummies like me - the Interleukin (IL-2) which was given to cohort B (which is the cohort with the two complete responses and one stable which may be upgraded - out of a cohort of 3) is a blood protein that is part of the body's immune system.

This was the key part of LC's press release:

“... one of the biggest challenges in CAR T-cell therapy is ensuring that the modified T-cells stay in the body long enough to kill cancer cells...to maximise the response rates and durability further, we added a very low dose of IL-2 to the regimen in Cohort B and early results suggest improved outcomes in patients.”

Once I knew what IL-2 was, that part of the release made more sense, and it explained why the the responses in cohort B were such great news. As I did not know what IL-2 was - I was also glad that it was not some sort of drug that was doing the heavy lifting in the cohort and merely taking Azer-cel along for a ride.

This is a huge plus.